Pub. Date : 2010
PMID : 20155988
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | The main outcome measure was the effect of ezetimibe on low-density lipoprotein cholesterol (LDL-C) and other lipid levels from baseline to 12 weeks. | Ezetimibe | component of oligomeric golgi complex 2 | Homo sapiens |
| 2 | The main outcome measure was the effect of ezetimibe on low-density lipoprotein cholesterol (LDL-C) and other lipid levels from baseline to 12 weeks. | Ezetimibe | component of oligomeric golgi complex 2 | Homo sapiens |
| 3 | The mean reduction in LDL-C level with ezetimibe monotherapy was significantly greater in patients with impaired LDL-C metabolism, glucose metabolism or hypertension than in those without such abnormalities (-21.0% vs -8.4%, p < 0.01; -22.7% vs -9.5%, p < 0.05; and -22.5% vs -5.9%, p < 0.05; respectively). | Ezetimibe | component of oligomeric golgi complex 2 | Homo sapiens |
| 4 | The reduction in LDL-C levels with ezetimibe monotherapy was also correlated with the number of metabolic abnormalities (rho = 0.426, p = 0.013). | Ezetimibe | component of oligomeric golgi complex 2 | Homo sapiens |
| 5 | CONCLUSIONS: Both ezetimibe monotherapy and combination therapy with ezetimibe and a statin were able to safely and effectively control LDL-C levels in Japanese patients with dyslipidaemia, including those with metabolic abnormalities. | Ezetimibe | component of oligomeric golgi complex 2 | Homo sapiens |
| 6 | CONCLUSIONS: Both ezetimibe monotherapy and combination therapy with ezetimibe and a statin were able to safely and effectively control LDL-C levels in Japanese patients with dyslipidaemia, including those with metabolic abnormalities. | Ezetimibe | component of oligomeric golgi complex 2 | Homo sapiens |